Mutational landscape influences immunotherapy outcomes among patients with non-small-cell lung cancer with human leukocyte antigen supertype B44

[1]  T. Chan,et al.  Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy , 2019, Nature Medicine.

[2]  J. Roth,et al.  PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung Cancer. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[3]  Alessandro Sette,et al.  The Immune Epitope Database (IEDB): 2018 update , 2018, Nucleic Acids Res..

[4]  Gabriel N. Teku,et al.  Pan-cancer analysis of neoepitopes , 2018, Scientific Reports.

[5]  G. Getz,et al.  Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors , 2018, Nature Genetics.

[6]  J. Szustakowski,et al.  Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden , 2018, The New England journal of medicine.

[7]  M. Berger,et al.  Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy , 2018, Science.

[8]  Astrid Gall,et al.  Ensembl 2018 , 2017, Nucleic Acids Res..

[9]  I. Mellman,et al.  Elements of cancer immunity and the cancer–immune set point , 2017, Nature.

[10]  T. Graeber,et al.  Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. , 2016, The New England journal of medicine.

[11]  J. Wolchok,et al.  Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. , 2016, JAMA.

[12]  Y. Shentu,et al.  Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial , 2016, The Lancet.

[13]  Nicolai J. Birkbak,et al.  Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade , 2016, Science.

[14]  E. Mardis,et al.  pVAC-Seq: A genome-guided in silico approach to identifying tumor neoantigens , 2016, Genome Medicine.

[15]  J. Lunceford,et al.  Pembrolizumab for the treatment of non-small-cell lung cancer. , 2015, The New England journal of medicine.

[16]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[17]  J. Wolchok,et al.  Genetic basis for clinical response to CTLA-4 blockade in melanoma. , 2014, The New England journal of medicine.

[18]  J. Sidney,et al.  Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity , 2014, The Journal of experimental medicine.

[19]  Benjamin J. Raphael,et al.  Mutational landscape and significance across 12 major cancer types , 2013, Nature.

[20]  Joshua M. Stuart,et al.  The Cancer Genome Atlas Pan-Cancer analysis project , 2013, Nature Genetics.

[21]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[22]  M. Zody,et al.  ATHLATES: accurate typing of human leukocyte antigen through exome sequencing , 2013, Nucleic acids research.

[23]  A. Sivachenko,et al.  A Landscape of Driver Mutations in Melanoma , 2012, Cell.

[24]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[25]  Pablo Cingolani,et al.  © 2012 Landes Bioscience. Do not distribute. , 2022 .

[26]  M. DePristo,et al.  A framework for variation discovery and genotyping using next-generation DNA sequencing data , 2011, Nature Genetics.

[27]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[28]  Roger L. Lundblad,et al.  Handbook of Biochemistry and Molecular Biology, Fifth Edition , 2010 .

[29]  T. Mok,et al.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.

[30]  J. Geddes,et al.  What is a randomised controlled trial? , 2009, Epidemiologia e Psichiatria Sociale.

[31]  C. Pace,et al.  A summary of the measured pK values of the ionizable groups in folded proteins , 2008, Protein science : a publication of the Protein Society.

[32]  B. Williams,et al.  Mapping and quantifying mammalian transcriptomes by RNA-Seq , 2008, Nature Methods.

[33]  Bjoern Peters,et al.  HLA class I supertypes: a revised and updated classification , 2008, BMC Immunology.

[34]  R. Glynn,et al.  Extension of the Rank Sum Test for Clustered Data: Two‐Group Comparisons with Group Membership Defined at the Subunit Level , 2006, Biometrics.

[35]  J. Drijfhout,et al.  Competition‐Based Cellular Peptide Binding Assay for HLA Class I , 2004, Current protocols in immunology.

[36]  C. Sander,et al.  The amino-acid mutational spectrum of human genetic disease , 2003, Genome Biology.

[37]  James McCluskey,et al.  A Naturally Selected Dimorphism within the HLA-B44 Supertype Alters Class I Structure, Peptide Repertoire, and T Cell Recognition , 2003, The Journal of experimental medicine.

[38]  N. Sinha,et al.  Electrostatics in protein binding and function. , 2002, Current protein & peptide science.

[39]  J. Sidney,et al.  Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism , 1999, Immunogenetics.

[40]  K. Parker,et al.  Identification of the peptide binding motif for HLA-B44, one of the most common HLA-B alleles in the Caucasian population. , 1995, Biochemistry.

[41]  M F del Guercio,et al.  Several HLA alleles share overlapping peptide specificities. , 1995, Journal of immunology.

[42]  J. Dausset.  The major histocompatibility complex in man. , 1981, Science.

[43]  L. Pauling,et al.  Molecules as documents of evolutionary history. , 1965, Journal of theoretical biology.

[44]  Hans-Georg Rammensee,et al.  MHC ligands and peptide motifs: first listing , 2004, Immunogenetics.

[45]  Jianzhi Zhang,et al.  Rates of Conservative and Radical Nonsynonymous Nucleotide Substitutions in Mammalian Nuclear Genes , 2000, Journal of Molecular Evolution.

[46]  F. Garrido,et al.  Altered MHC class I antigens in tumors , 1997, International journal of clinical & laboratory research.